Yellowstone Biosciences launches with £16.5 million to pioneer soluble bispecific TCR-based therapies for cancer
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: Business Wire
New oncology company created to unlock a novel class of therapeutics targeting human leukocyte antigen (HLA) Class II expression in a range of common cancersSpun out of the University of Oxford from the pioneering work of Professor Paresh Vyas, initially starting in acute myeloid leukaemia (AML) with broader pipeline potential across a range of cancers£16.5 million in Series A funding from lead investor Syncona to progress operational build, lead programme and potential pipeline expansion. OXFORD, England--(BUSINESS WIRE)--Yellowstone Biosciences (“Yellowstone” or “the Company”), a pioneer of soluble bispecific T-cell receptor (TCR)-based therapies for human leukocyte antigen (HLA) Class II (HLA-II) targets in oncology, launches today to unlock a new class of therapeutically targetable, frequently expressed antigens with potential to significantly transform patient lives. Syncona Limited (“Syncona”) committed £16.5 million to fund the Company in progressing its operational build, l
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore Holdings plc (NASDAQ: IMCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Immunocore Holdings plc (NASDAQ: IMCR) had its price target lowered by analysts at Needham & Company LLC from $81.00 to $78.00. They now have a "buy" rating on the stock.MarketBeat
- Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancerGlobeNewswire
- Immunocore to present at the 2024 Cantor Global Healthcare ConferenceGlobeNewswire
- Immunocore Holdings plc (NASDAQ: IMCR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
IMCR
Earnings
- 8/8/24 - Beat
IMCR
Sec Filings
- 9/16/24 - Form 8-K
- 9/10/24 - Form SC
- 8/29/24 - Form 8-K
- IMCR's page on the SEC website